web analytics

Safe and well tolerated dose of C21 established in successful dose escalation phase 1 study

Gothenburg , September 6, 2019 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, announced today that it has completed a 54-subject phase I dose-escalation study in the company’s VP01 project investigating the drug candidate C21, a first in class, oral, angiotensin II type 2 receptor (AT2R) agonist. The study established that 200 mg daily has a good safety profile and that it was the maximum tolerated dose. This dose will be used in the planned phase II studies in idiopathic pulmonary fibrosis (IPF) and diffuse

Source: Safe and well tolerated dose of C21 established in successful dose escalation phase 1 study

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.